Published in Nat Rev Clin Oncol on July 26, 2011
Riluzole prodrugs for melanoma and ALS: design, synthesis, and in vitro metabolic profiling. Bioorg Med Chem (2012) 1.02
Therapeutic antibodies against cancer. Hematol Oncol Clin North Am (2012) 0.87
Evaluation of stromal HGF immunoreactivity as a biomarker for melanoma response to RAF inhibitors. Mod Pathol (2014) 0.83
Immunity to melanin and to tyrosinase in melanoma patients, and in people with vitiligo. BMC Complement Altern Med (2012) 0.77
Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med (2010) 67.34
Mutations of the BRAF gene in human cancer. Nature (2002) 65.42
Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med (2011) 45.46
Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med (2011) 26.90
High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J Clin Oncol (1999) 10.86
gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma. N Engl J Med (2011) 5.15
Systematic review of medical treatment in melanoma: current status and future prospects. Oncologist (2011) 2.89
The histologic spectrum of epithelial neoplasms induced by sorafenib. J Am Acad Dermatol (2009) 2.74
Melanoma--an unlikely poster child for personalized cancer therapy. N Engl J Med (2010) 1.47
Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma. J Clin Oncol (2005) 4.64
Adjuvant immunotherapy of resected, intermediate-thickness, node-negative melanoma with an allogeneic tumor vaccine: impact of HLA class I antigen expression on outcome. J Clin Oncol (2002) 3.05
A phase 2 trial of complete resection for stage IV melanoma: results of Southwest Oncology Group Clinical Trial S9430. Cancer (2011) 1.66
Risk assessment in localized primary cutaneous melanoma: a Southwest Oncology Group study evaluating nine factors and a test of the Clark logistic regression prediction model. Am J Clin Pathol (2002) 1.57
ACCO: ASCO core curriculum outline. J Clin Oncol (2005) 1.20
Adjuvant immunotherapy of resected, intermediate-thickness, node-negative melanoma with an allogeneic tumor vaccine: overall results of a randomized trial of the Southwest Oncology Group. J Clin Oncol (2002) 1.15
Randomized phase II trial of sorafenib with temsirolimus or tipifarnib in untreated metastatic melanoma (S0438). Clin Cancer Res (2012) 1.04
A phase II trial of imatinib mesylate in merkel cell carcinoma (neuroendocrine carcinoma of the skin): A Southwest Oncology Group study (S0331). Am J Clin Oncol (2010) 0.96
Adjuvant therapy of melanoma: is pegylated interferon alfa-2b what we've been waiting for? Lancet (2008) 0.90
SWOG S0215: a phase II study of docetaxel and vinorelbine plus filgrastim with weekly trastuzumab for HER2-positive, stage IV breast cancer. Breast Cancer Res Treat (2011) 0.87
Phase 2 trial of combination thalidomide plus temozolomide in patients with metastatic malignant melanoma: Southwest Oncology Group S0508. Cancer (2010) 0.81
Phase II trial of pegylated interferon and thalidomide in malignant metastatic melanoma. Anticancer Drugs (2007) 0.79
Evaluation of interferon alpha-2B and thalidomide in patients with disseminated malignant melanoma, phase 2, SWOG 0026. Cancer (2007) 0.79
Phase II trial of interferon and thalidomide in metastatic renal cell carcinoma. Invest New Drugs (2006) 0.77
A phase II trial of pyrazine diazohydroxide in patients with disseminated malignant melanoma and no prior chemotherapy--Southwest Oncology Group study. Invest New Drugs (2002) 0.75
New options for the adjuvant treatment of cutaneous melanoma? Curr Oncol Rep (2014) 0.75